The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector
Open accessAbstract
Efforts to develop drugs for Alzheimer's disease (AD) have shown promise in animal studies, only to fail in human trials, suggesting a pressing need to study AD in human model systems. Using human neurons derived from induced pluripotent stem cells that expressed apolipoprotein E4 (ApoE4), a variant of the APOE gene product and the major genetic risk factor for AD, we demonstrated that ApoE4-expressing neurons had higher levels of tau phosphorylation, unrelated to their increased production of amyloid-β (Aβ) peptides, and that they displayed GABAergic neuron degeneration. ApoE4 increased Aβ production in human, but not in mouse, neurons. Converting ApoE4 to ApoE3 by gene editing rescued these phenotypes, indicating the specific effects of ApoE4. Neurons that lacked APOE behaved similarly to those expressing ApoE3, and the introduction of ApoE4 expression recapitulated the pathological phenotypes, suggesting a gain of toxic effects from ApoE4. Treatment of ApoE4-expressing neurons with a small-molecule structure corrector ameliorated the detrimental effects, thus showing that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“but late-stage neuropathological features, such as formation of insoluble tau and neurodegeneration have not been reported.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [17]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“iPSC-derived neurons from individuals with AD exhibit increased production of Aβ42, active GSK-3β, phosphorylated tau, endosomal abnormalities, and oxidative stress (12–17)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It exacerbates AD-related pathologies, including amyloid-beta (Aβ) plaques, Tau tangles, neurodegeneration and neuroinflammation4–16.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Research in animal models (Bien-Ly et al., 2012) and hiPSC-based models (Wang et al., 2018) has indicated that the APOE3 genotype leads to higher total APOE levels compared to the APOE4 genotype.”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Wang et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies with mouse (Andrews-Zwilling et al., 2010) and hiPSC-based (Wang et al., 2018) systems have shown that APOE genotypes might influence GABAergic interneuron generation and survival.”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Wang et al., 2018
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, APOE3ch did not affect APOE secretion, consistent with prior work demonstrating that APOE stability and secretion are primarily isoform-dependent (E4 < E3 < E2) (Bien-Ly et al., 2012; Wang et al., 2018) and that the Christchurch R136S substitution likely influences receptor-binding and HSPG interactions rather than secretion pathways.”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Wang et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple small molecules have been designed to ‘correct’ the conformation of APOE4 so that it resembles that of APOE3 or APOE2 (refs. 213–217)”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some of these molecules have been shown to be effective in cell models, whereas others are in even earlier stages of development216,217.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies with human iPSC-derived neurons and organoids confirm that apoE4 increases Aβ production and aggregation as well as decreases Aβ clearance”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Wang et al 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies with human iPSC-derived neurons and cerebral organoids demonstrate that apoE4 enhances tau phosphorylation and exacerbates synapse loss and neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Wang et al 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Isogenic APOE4/4 and APOE3/3 iPS cells were generated as previously described16.”
From APOE4/4 is linked to damaging lipid droplets in Alzheimer’s disease microglia (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“As reported previously6, the E4 neuron culture had a lower fraction of GABA+ inhibitory neurons than the E3 neuron culture (Supplementary Fig. 2c,d).”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Western blotting analysis of cell lysates with PHF1 and AT8 antibodies revealed that the E3 neurons had a significant reduction in p-Tau levels compared to E4 neurons (Fig. 2a,c,d and Supplementary Fig. 3b,c), confirming our previous report6.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Immunocytochemistry analysis confirmed that MAP2+ neurons expressed APOE (Supplementary Fig. 2a), as reported previously6.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“hiPSC lines were then differentiated into neurons expressing mature neuronal marker MAP2 (Extended Data Fig. 3c) via an optimized method using dual-SMAD inhibition6,56.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Such correctors have already been shown to restore ApoE3-like behavior in iPSC-derived neurons (37,48)”
From APOE Isoform-Dependent Self-Association Measured by a Split-Luciferase Complementation Assay: Differential Effects of Disease-Risk and Protective Variants (2026) · cites this paper as [48]
The cited source says what the claim attributes to it.
In the citing paper
“We also observe apoptotic pathways, including activation of BH3-only proteins (Reactome:R-HSA-114452) and apoptosis (Reactome:R-HSA-109581, Supp. Table S36), suggesting a potential role of APOE40–42 in cell death.”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [41]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, treating ApoE4-expressing iPSC-derived neurons with PH002, another structure corrector, was able to ameliorate the toxic effects induced by this isoform of ApoE, by reducing ApoE4 detrimental effect on neurite outgrowth in Neuro-2a cells and dendritic spine development in primary neurons [85], increasing the number of GABAergic neurons and reducing P-tau, Aβ40 and Aβ42 levels [86].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [86]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, treating ApoE4-expressing iPSC-derived neurons with PH002, another structure corrector, was able to ameliorate the toxic effects induced by this isoform of ApoE, by reducing ApoE4 detrimental effect on neurite outgrowth in Neuro-2a cells and dendritic spine development in primary neurons [85], increasing the number of GABAergic neurons and reducing P-tau, Aβ40 and Aβ42 levels [86].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [86]
The cited source says what the claim attributes to it.
In the citing paper
“Similar co-regulation of Aβ and Tau through independent pathways have recently been shown for ApoE (Wang et al., 2018) and the retromer complex (Young et al., 2018).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Wang et al., 2018
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“suggesting that the R136S mutation results in less APOE4 fragmentation6.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“For example, apoE4/4 neurons produced significantly more Aβ and phosphorylated tau than apoE3/3 neurons.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [128]
In the citing paper
“Strikingly, much of AD pathology seen in vivo was successfully recapitulated in this hiPSC-derived neuronal model in vitro.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [128]
In the citing paper
“the use of a structure corrector has been shown in vitro to ameliorate apoE4-mediated AD pathologies in hiPSC-derived neurons, including GABAergic neuron deficits [128].”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Self-citationThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
APP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265
Cited by
Sorted by citations
Items 101–200 of 429
Zhou, C., Sun, X., Hu, Y., Song, J., Dong, S., Kong, D., Wang, Y., Hua, X., Han, J., Zhou, Y., et al. (2019) · Aging · doi:10.18632/aging.102260 · Cited by 50
Yang, A., Kantor, B., & Chiba‐Falek, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031244 · Cited by 51
Physiological and Pathological Ageing of Astrocytes in the Human Brain
Verkerke, M., Hol, E. M., & Middeldorp, J. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03256-7 · Cited by 51
Xiong, J., Kang, S. S., Wang, M., Wang, Z., Xia, Y., Liao, J., Liu, X., Yu, S. P., Zhang, Z., Ryu, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42282-7 · Cited by 51
Berry, B. J., Smith, A. S. T., Young, J. E., & Mack, D. L. (2018) · Cells Tissues Organs · doi:10.1159/000493018 · Cited by 47
iPSC for modeling neurodegenerative disorders
Valadez-Barba, V., Cota-Coronado, A., Hernandez-Perez, O. R., Lugo-Fabres, P. H., Padilla‐Camberos, E., Díaz, N. F., & Diaz-Martinez, N. E. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.11.006 · Cited by 49
Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery
Lu, Q., & Julia, T. C. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031203 · Cited by 49
Wang, Z.-H., Xia, Y., Liu, P., Liu, X., Edgington‐Mitchell, L. E., Lei, K., Yu, S. P., Wang, X., & Ye, K. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102032 · Cited by 48
Raulin, A.-C., Kraft, L., Al-Hilaly, Y. K., Xue, W.-F., McGeehan, J. E., Atack, J. R., & Serpell, L. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.04.019 · Cited by 47
Contribution of astrocytes to metabolic dysfunction in the Alzheimer’s disease brain
Zulfiqar, S., Garg, P., & Nieweg, K. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0140 · Cited by 46
Sen, T., & Thummer, R. P. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00564-w · Cited by 52
Chen, Y., Jin, H., Chen, J., Li, J., Găman, M., & Zou, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02600-y · Cited by 56
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Rudajev, V., & Novotný, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01127-y · Cited by 52
A multi‐hit hypothesis for an APOE4 ‐dependent pathophysiological state
Steele, O. G., Stuart, A. C., Minkley, L., Shaw, K., Bonnar, O., Anderle, S., Penn, A. C., Rusted, J., Serpell, L., Hall, C., et al. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15685 · Cited by 44
APOEε4 potentiates amyloid β effects on longitudinal tau pathology
Ferrari-Souza, J. P., Bellaver, B., Ferreira, P. C. L., Benedet, A. L., Povala, G., Lussier, F. Z., Leffa, D. T., Therriault, J., Tissot, C., Soares, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00490-2 · Cited by 43
Bose, A., & Beal, M. F. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14264 · Cited by 43
Raikwar, S. P., Kikkeri, N. S., Sakuru, R. C., Saeed, D., Zahoor, H., Premkumar, K., Mentor, S., Thangavel, R., Dubova, I., Ahmed, M. E., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09849-y · Cited by 48
MicroRNAs in Extracellular Vesicles of Alzheimer’s Disease
Li, W., & Zheng, Y. (2023) · Cells · doi:10.3390/cells12101378 · Cited by 43
Targeting Apolipoprotein E for Alzheimer’s Disease: An Industry Perspective
Suidan, G. L., & Ramaswamy, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092161 · Cited by 42
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 41
Manzo, C., Mestres, J. S., Isetta, M., & Castagna, A. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110479 · Cited by 43
Stem Cell Therapies in Alzheimer’s Disease: Applications for Disease Modeling
Si, Z., & Wang, X. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.000324 · Cited by 42
Ahmed, M. M., Johnson, N. R., Boyd, T. D., Coughlan, C. M., Chial, H. J., & Potter, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718426 · Cited by 42
Human iPSC application in Alzheimer’s disease and tau-related neurodegenerative diseases
TCW, J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.01.043 · Cited by 39
Rao, A. T., Chen, N., Kim, M. J., Blumenfeld, J. R., Yip, O., Liang, Z., Shostak, D. M., Hao, Y., Nelson, M. R., Koutsodendris, N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.005 · Cited by 48
Self-citationMulti-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 43
Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases
Zhang, X., Hu, D., Shang, Y., & Qi, X. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.03.004 · Cited by 36
High‐affinity multivalent interactions between apolipoprotein E and the oligomers of amyloid‐β
Ghosh, S., Sil, T. B., Dolai, S., & Garai, K. (2019) · FEBS Journal · doi:10.1111/febs.14988 · Cited by 40
Critical Molecular and Cellular Contributors to Tau Pathology
Song, L., Wells, E. A., & Robinson, A. S. (2021) · Biomedicines · doi:10.3390/biomedicines9020190 · Cited by 40
The Role of HDL and HDL Mimetic Peptides as Potential Therapeutics for Alzheimer’s Disease
Chernick, D., Zhong, R., & Li, L. (2020) · Biomolecules · doi:10.3390/biom10091276 · Cited by 39
Apolipoprotein E isoform-dependent effects on the processing of Alzheimer's amyloid-β
Chai, A. B., Lam, H. H. J., Kockx, M., & Gelissen, I. C. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158980 · Cited by 41
Sawmiller, D. R., Habib, A., Hou, H., Mori, T., Fan, A., Tian, J., Jin, Z., Giunta, B. N., Sanberg, P. R., Mattson, M. P., et al. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.04.026 · Cited by 38
RetractedModelling Sporadic Alzheimer’s Disease Using Induced Pluripotent Stem Cells
Rowland, H. A., Hooper, N. M., & Kellett, K. A. B. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2663-z · Cited by 38
Modeling Alzheimer’s disease with human iPS cells: advancements, lessons, and applications
Essayan-Perez, S., Zhou, B., Nabet, A. M., Wernig, M., & Huang, Y. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104503 · Cited by 40
Self-citationYang, M., Lian, N., Yu, Y., Wang, Y., Xie, K., & Yu, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11131 · Cited by 37
Sun, G. G., Wang, C., Mazzarino, R. C., Perez-Corredor, P. A., Davtyan, H., Blurton-Jones, M., Lopera, F., Arboleda-Velasquez, J. F., & Shi, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114982 · Cited by 36
Self-citationJablonski, A. M., Warren, L., Usenovic, M., Zhou, H. H., Sugam, J. A., Parmentier‐Batteur, S., & Voleti, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-82901-1 · Cited by 38
The Role of Genetic, Environmental, and Dietary Factors in Alzheimer’s Disease: A Narrative Review
Mertaş, B., & Boşgelmez, İ. İ. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031222 · Cited by 35
Re-thinking Alzheimer's disease therapeutic targets using gene-based tests
Kwok, M. K., Lin, S. L., & Schooling, C. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.001 · Cited by 35
The application of in vitro ‐derived human neurons in neurodegenerative disease modeling
D’Souza, G. X., Rose, S. E., Knupp, A., Nicholson, D. A., Keene, C. D., & Young, J. E. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24615 · Cited by 36
García‐León, J. A., Cáceres-Palomo, L., Sánchez‐Mejías, E., Mejias‐Ortega, M., Nuñez‐Diaz, C., Fernandez-Valenzuela, J. J., Sanchez-Varo, R. M., Dávila, J. C., Vitórica, J., & Gutiérrez, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186867 · Cited by 35
Choe, M. S., Yeo, H. C., Kim, J., Lee, J., Lee, H. J., Kim, H., Baek, K. M., Jung, N., Choi, M., & Lee, M. Y. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03732-1 · Cited by 39
APOE2 mitigates disease-related phenotypes in an isogenic hiPSC-based model of Alzheimer’s disease
Brookhouser, N., Raman, S., Frisch, C., Srinivasan, G., & Brafman, D. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01076-3 · Cited by 33
Cell Type Impacts Accessibility of mRNA to Silencing by RNA Interference
Ferguson, C. M., Echeverria, D., Hassler, M. R., Ly, S., & Khvorova, A. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.06.006 · Cited by 34
Ramakrishna, S., Jhaveri, V., Konings, S. C., Nawalpuri, B., Chakraborty, S., Holst, B., Schmid, B., Gouras, G. K., Freude, K., & Muddashetty, R. S. (2021) · Journal of Neuroscience · doi:10.1523/jneurosci.0435-21.2021 · Cited by 34
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Alzheimer’s in a dish – induced pluripotent stem cell-based disease modeling
de Leeuw, S., & Tackenberg, C. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0161-0 · Cited by 31
Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer
Petros, A. M., Korepanova, A., Jakob, C. G., Qiu, W., Panchal, S. C., Wang, J., Dietrich, J. D., Brewer, J. T., Pohlki, F., Kling, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00178 · Cited by 32
Kantor, B., O’Donovan, B., & Chiba‐Falek, O. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102635 · Cited by 38
Liu, Z., Chao, J., Wang, C., Sun, G., Roeth, D., Liu, W., Chen, X., Li, L., Tian, E., Feng, L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112841 · Cited by 30
Self-citationNemergut, M., Marques, S. M., Uhrik, L., Vanova, T., Nezvedova, M., Gadara, D. C., Jha, D., Tulis, J., Novakova, V., Planas-Iglesias, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00620-9 · Cited by 30
Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 37
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 32
Alzheimer’s disease: a tale of two diseases?
Nardini, E., Hogan, R., Flamier, A., & Bernier, G. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.308070 · Cited by 33
Alzheimer's disease and synapse Loss: What can we learn from induced pluripotent stem Cells?
Rodríguez-Jiménez, F. J., Ureña‐Peralta, J. R., Jendelová, P., & Erceg, S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.006 · Cited by 33
Bio–Nano Toolbox for Precision Alzheimer's Disease Gene Therapy
Liu, Y., Xia, X., Zheng, M., & Shi, B. (2024) · Advanced Materials · doi:10.1002/adma.202314354 · Cited by 31
García‐León, J. A., Vitórica, J., & Gutiérrez, A. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0520 · Cited by 30
Potential Role of Extracellular CIRP in Alcohol-Induced Alzheimer’s Disease
Sharma, A., Brenner, M., & Wang, P. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02075-1 · Cited by 28
CRISPR-Cas9 for treating hereditary diseases
Mani, I. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.017 · Cited by 33
Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases
Trudler, D., Ghatak, S., & Lipton, S. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158196 · Cited by 30
Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer’s disease
Qian, Z., Wang, Z., Li, B., Meng, X., Kuang, Z., Li, Y., Yang, Y., & Ye, K. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02565-x · Cited by 28
Kondo, T., Hara, N., Koyama, S., Yada, Y., Tsukita, K., Nagahashi, A., Ikeuchi, T., Ishii, K., Asada, T., Arai, T., et al. (2022) · Nature Aging · doi:10.1038/s43587-021-00158-9 · Cited by 26
Chen, J., Zhao, S., Zhou, Y., Wang, L., Chen, Q., & Zheng, K. (2025) · BioScience Trends · doi:10.5582/bst.2025.01148 · Cited by 29
The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease
Bendtsen, K. M., & Hall, V. J. (2023) · Cells · doi:10.3390/cells12030420 · Cited by 30
Poblano, J., Castillo‐Tobías, I., Berlanga, L., Tamayo‐Ordoñez, M. C., Rodríguez‐Salazar, M. D. C., Silva‐Belmares, S. Y., Aguayo‐Morales, H., & Cobos-Puc, L. E. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.14055 · Cited by 29
Mountaki, C., Dafnis, I., Panagopoulou, E. A., Vasilakopoulou, P. B., Karvelas, M., Chiou, A., Karathanos, V. Τ., & Chroni, A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.022 · Cited by 28
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 27
Zhao, J., Ikezu, T. C., Lu, W., Macyczko, J. R., Li, Y., Lewis-Tuffin, L. J., Martens, Y. A., Ren, Y., Zhu, Y., Asmann, Y. W., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03444-y · Cited by 25
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
Lozupone, M., Imbimbo, B. P., Balducci, C., Vecchio, F. L., Bisceglia, P., Latino, R. R., Leone, M. A., Dibello, V., Solfrizzi, V., Greco, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12728 · Cited by 28
Cross interactions between Apolipoprotein E and amyloid proteins in neurodegenerative diseases
Loch, R. A., Wang, H., Perálvarez‐Marín, A., Berger, P., Nielsen, H. M., Chroni, A., & Luo, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.022 · Cited by 26
APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease
Ayyubova, G. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666230303114425 · Cited by 23
Implication of tau propagation on neurodegeneration in Alzheimer’s disease
Lamontagne-Kam, D., Ulfat, A. K., Hervé, V., Vu, T.-M., & Brouillette, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1219299 · Cited by 28
He, K., Nie, L., Zhou, Q., Rahman, S. U., Liu, J., Yang, X., & Li, S. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00136 · Cited by 24
The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling
Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 24
Macyczko, J. R., Wang, N., Zhao, J., Ren, Y., Lü, W., Ikezu, T. C., Zhao, N., Liu, C., Bu, G., & Li, Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03065-1 · Cited by 25
An Alzheimer’s-disease-protective APOE mutation
Zalocusky, K. A., Nelson, M. R., & Huang, Y. (2019) · Nature Medicine · doi:10.1038/s41591-019-0634-9 · Cited by 25
Self-citationThe proportion of Alzheimer’s disease attributable to apolipoprotein E
Williams, D. M., Heikkinen, S., Hiltunen, M. O., FinnGen, Davies, N. M., & Anderson, E. L. (2026) · npj Dementia · doi:10.1038/s44400-025-00045-9 · Cited by 27
Qu, W., Canoll, P., & Hargus, G. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.006 · Cited by 24
Johnson, N. R., Wang, A. C.-J., Coughlan, C. M., Sillau, S., Lucero, E., Viltz, L., Markham, N. E., Allen, C., Dhanasekaran, A. R., Chial, H. J., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01020-9 · Cited by 24
Kim, H., Kim, S., Cho, B., Shin, J., & Kim, J. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00319-9 · Cited by 22
Koutsodendris, N., Blumenfeld, J. R., Agrawal, A., Traglia, M., Yip, O., Rao, A. T., Kim, M. J., Nelson, M. R., Wang, Y.-H., Grone, B. P., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113252 · Cited by 25
Self-citationKim, Y. W., Al‐Ramahi, I., Koire, A. M., Wilson, S. J., Konecki, D. M., Mota, S., Soleimani, S., Botas, J., & Lichtarge, O. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12240 · Cited by 22
Ding, Y., Palecek, S. P., & Shusta, E. V. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00580-2 · Cited by 22
γ-Secretase Modulatory Proteins: The Guiding Hand Behind the Running Scissors
Wong, E., Frost, G. R., & Li, Y. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.614690 · Cited by 23
Habenicht, L. K. L., Wang, Z., Zhang, X., Li, Y., Mogler, C., Huspenina, J. S., Schmid, R. M., Weber, C., Mohanta, S. K., Ma, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970938 · Cited by 23
Hou, X., Zhang, X., Zou, H., Guan, M., Fu, C., Wang, W., Zhang, Z.-R., Geng, Y., & Chen, Y. (2023) · Neuron · doi:10.1016/j.neuron.2023.03.024 · Cited by 23
Zhou, X., Fu, A. K. Y., & Ip, N. Y. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.02.001 · Cited by 23
Gene and RNA Editing: Revolutionary Approaches to Treating Diseases
Li, J., Huang, J., Liao, Y., Hu, T., Wang, C., Zhang, W., & Huang, C. (2025) · MedComm · doi:10.1002/mco2.70389 · Cited by 23
Self-citationStem cells: A path towards improved epilepsy therapies
Lybrand, Z. R., Goswami, S., & Hsieh, J. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107781 · Cited by 22
Lysosomal proteomics reveals mechanisms of neuronal APOE4-associated lysosomal dysfunction
Krogsaeter, E., McKetney, J., Valiente‐Banuet, L., Marquez, A., Willis, A., Cakir, Z., Stevenson, E. J., Jang, G. Μ., Rao, A. T., Li, E., et al. (2025) · Autophagy · doi:10.1080/15548627.2025.2576613 · Cited by 22
Self-citationYan, Y., Bejoy, J., Marzano, M., & Li, Y. (2019) · Cells · doi:10.3390/cells8030242 · Cited by 21
Genomics: New Light on Alzheimer’s Disease Research
Jung, Y. J., Kim, Y. H., Bhalla, M., Lee, S. B., & Seo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123771 · Cited by 19
APOE4/4 is linked to damaging lipid droplets in Alzheimer’s microglia
Haney, M. S., Pálovics, R., Munson, C. N., Long, C., Johansson, P., Yip, O., Dong, W., Rawat, E., West, E., Schlachetzki, J. C., et al. (2023) · doi:10.1101/2023.07.21.549930 · Cited by 20
Self-citationAPOE4 impacts cortical neurodevelopment and alters network formation in human brain organoids
Meyer-Acosta, K. K., Díaz‐Guerra, E., Varma, P., Aruk, A., Mirsadeghi, S., Perez, A. M., Rafati, Y., Hosseini, A., Nieto‐Estévez, V., Giugliano, M., et al. (2025) · Stem Cell Reports · doi:10.1016/j.stemcr.2025.102537 · Cited by 19
Guerreiro, S. R., & Maciel, P. (2023) · Cells · doi:10.3390/cells12040538 · Cited by 20
Ruan, H., Zhang, J., Wang, Y., Huang, Y., Wu, J., He, C., Ke, T., Luo, J., & Yang, M. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.08.002 · Cited by 22
Self-citationVidal, C., & Li, Z. (2021) · Cells · doi:10.3390/cells10030546 · Cited by 20
Implications for microglial sex differences in tau-related neurodegenerative diseases
Doust, Y. V., King, A. E., & Ziebell, J. M. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.03.010 · Cited by 18
Metadata
- Authors
- Wang, C., Najm, R., Xu, Q., Jeong, D.-E., Walker, D., Balestra, M. E., Yoon, S. Y., Yuan, H., Li, G., Miller, Z. A., Miller, B. L., Malloy, M. J., & Huang, Y.
- Affiliations
- Gladstone Institutes (US)
- University of California, San Francisco (US)
- Corresponding author
- Huang, Yadong
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-04-09
- Volume
- 24
- Issue
- 5
- Pages
- 647-657
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC5948154
- OpenAlex
- W2798230823
- Cited by
- 428
- References
- 62
- Citations by year
- 2026: 36 · 2025: 45 · 2024: 69 · 2023: 57 · 2022: 54 · 2021: 48 · 2020: 58 · 2019: 42 · 2018: 18
- FWCI
- 28.54
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- California Institute for Regenerative Medicine (TRAN1-09394, RN2-00952)
- Roddenberry Foundation
- National Institutes of Health (AG023501)
- National Institute on Aging (RF1AG048030, R01AG056305, K23AG048291, R01AG048017, P50AG023501)
- National Institute of Allergy and Infectious Diseases (P30AI027763)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- APOE ε4, Alzheimer's disease, gain-of-function, iPSC-derived neurons, tau phosphorylation, amyloid-beta production, genome editing, APOE3, human disease models, therapeutic target
- MeSH terms
- Gene Editing, Alzheimer Disease, Cell Line, Cells, Cultured, Homozygote, Humans, Nerve Degeneration, Neurons, Phosphorylation, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Apolipoprotein E3, Apolipoprotein E4, Small Molecule Libraries, Induced Pluripotent Stem Cells, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
